<DOC>
	<DOCNO>NCT00296023</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine busulfan , donor bone marrow peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin transplant methotrexate tacrolimus transplant may stop happen . PURPOSE : This phase I trial study side effect donor stem cell transplant treat old frail patient hematologic cancer .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Older Frail Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety non-myeloablative allogeneic peripheral blood stem cell transplantation , term regimen-related organ toxicity toxicity acute graft-vs-host disease ( GVHD ) , old medically frail patient high-risk indolent hematologic malignancy . - Determine overall survival , disease-free survival , relapse risk 1 , 2 , 3 year post-transplantation patient . Secondary - Determine engraftment donor hematopoiesis 6 week , 3 6 month , 1 year post-transplantation patient . - Determine incidence severity chronic GVHD older medically infirm patient treated regimen . - Determine safety efficacy collect peripheral blood stem cell old donor ( age &gt; 60 year ) . - Determine need efficacy donor lymphocyte infusion patient residual disease transplant . OUTLINE : - Non-myeloablative preparative regimen : Patients receive fludarabine IV 30 minute day -7 -3 , busulfan IV 2 hour every 8 hour day -4 -3 , anti-thymocyte globulin IV 8 hour day -4 -1 . - Transplantation : Patients undergo allogeneic peripheral blood stem cell transplantation day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 6 continue blood count recover . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive tacrolimus orally every 12 hour IV continuously begin day -2 continue day 90 , follow taper day 180 . Patients also receive methotrexate IV 15-30 minute day 1 , 3 , 6 , 11 . - Donor lymphocyte infusion ( DLIs ) : Patients residual disease ≥ 6 month post-transplantation immunosuppression ≥ 30 day evidence GVHD may receive DLIs . DLIs administer ≥ 12 week apart presence persistent disease , absence severe ( grade 3-4 ) GVHD , absence persistent GVHD first DLI . After completion study therapy , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highrisk indolent hematologic malignancy meeting follow criterion : Chronic lymphocytic leukemia ( CLL ) meet 1 follow criterion : In second subsequent remission Failed achieve complete remission ( CR ) chemotherapy NonHodgkin 's lymphoma ( NHL ) meet 1 follow criterion : Lowgrade NHL meet 1 follow criterion : Standardrisk disease second subsequent remission Standardrisk disease fail achieve CR chemotherapy In first subsequent remission adverse International Prognostic Index ( IPI ) prognostic feature , define presence ≥ 3 following : Age &gt; 60 year Tumor stage III IV Extranodal disease &gt; 1 site ECOG performance status ≥ 2 Serum lactic dehydrogenase ( LDH ) &gt; upper limit normal ( ULN ) Intermediate highgrade NHL meet 1 follow criterion : In second subsequent remission Failed achieve CR initial chemotherapy Waldenstrom 's macroglobulinemia meeting 1 follow criterion : In second subsequent remission Failed achieve CR initial chemotherapy Multiple myeloma meeting 1 follow criterion : In first subsequent remission Failed achieve CR initial chemotherapy Myeloproliferative disorder , include follow : Chronic myelogenous leukemia first subsequent chronic phase Myelofibrosis Essential thrombocytopenia poorly responsive standard therapy Polycythemia vera poorly responsive standard therapy spent phase Prolymphocytic leukemia meet 1 follow criterion : In first subsequent remission Failed achieve CR initial chemotherapy Mantle cell lymphoma meet 1 follow criterion : In first subsequent remission Failed achieve CR initial chemotherapy Hodgkin 's lymphoma meeting follow criterion : In second subsequent remission Prior remission duration &gt; 6 month No radiation therapy prior primary therapy Myelodysplastic syndrome ( MDS ) meet 1 follow criterion : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Any MDS transfusion dependence Any MDS ≥ 2 significant infection Acute myeloid leukemia morphologic remission In CR partial remission stabilization disease standard chemotherapy No progressive refractory disease Not eligible standard allogeneic bone marrow transplantation Meets 1 follow criterion : Age 60 75 year old AND comorbid illness Younger patient follow comorbidities : Decreased cardiac ejection fraction Pulmonary dysfunction Elevated liver function test Hepatitis C infection Poor performance status Sibling relate donor available Matched ≥ 5/6 HLA locus ( A , B , DR ) NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : See Disease Characteristics ECOG performance status 02 Creatinine &lt; 2.0 mg/dL Creatinine clearance &gt; 40 mL/min Ejection fraction &gt; 30 % echocardiogram MUGA Bilirubin &lt; 3.0 mg/dL ( total bilirubin elevate Gilbert 's disease suspect , direct bilirubin must normal ) Alkaline phosphatase &lt; 4 time ULN AST &lt; 4 time ULN HIV negative Hepatitis B and/or C virus allow liver biopsy ( perform within past 3 month ) show ≤ grade 2 inflammation No active infection PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
</DOC>